Table 20-7.
National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care
| Commercial, % |
Medicare, % |
Medicaid, % |
|
|---|---|---|---|
| Acute MI | |||
| β-blocker persistence* | 75.0 | 79.7 | 73.6 |
| Cholesterol management for patients with CAD | |||
| Cholesterol screening | 88.9 | 88.6 | 79.6 |
| LDL control (<100 mg/dL) | 59.7 | 56.7 | 40.1 |
| Hypertension | |||
| BP <140/90 mm Hg | 63.4 | 58.5 | 55.8 |
| DM | |||
| HbA1c testing | 89.0 | 88.3 | 80.5 |
| HbA1c >9.0% | 28.4 | 29.4 | 44.8 |
| Eye examination performed | 56.5 | 60.8 | 52.8 |
| LDL cholesterol screening | 84.8 | 86.3 | 74.1 |
| LDL cholesterol <100 mg/dL | 45.5 | 48.7 | 33.8 |
| Monitoring nephropathy | 82.4 | 87.9 | 76.6 |
| BP <130/80 mm Hg | 33.4 | 31.8 | 30.7 |
| BP <140/90 mm Hg | 65.6 | 59.5 | 56.9 |
| Advising smokers to quit | 76.7 | N/A | 69.3 |
MI indicates myocardial infarction; CAD, coronary artery disease; LDL, low-density lipoprotein; BP, blood pressure; DM, diabetes mellitus; HbA1c, glycosylated hemoglobin.
*
β-blocker persistence: Received persistent β-blocker treatment for 6 months after hospital discharge for acute MI.